Profile data is unavailable for this security.
About the company
Propanc Biopharma, Inc. is an Australia-based clinical biopharmaceutical company. The Company is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development. Its drug pipeline also includes POP1.
- Revenue in USD (TTM)0.00
- Net income in USD-2.46m
- Incorporated2010
- Employees1.00
- LocationPropanc Biopharma Inc302/6 Butler Street, CamberwellMELBOURNE 3124AustraliaAUS
- Phone+61 39882-0780
- Fax+61 39208-4110
- Websitehttps://www.propanc.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| eFFECTOR Therapeutics Inc | 0.00 | -34.63m | 203.47k | 14.00 | -- | 0.2041 | -- | -- | -13.31 | -13.31 | 0.00 | 0.2119 | 0.00 | -- | -- | 0.00 | -141.18 | -- | -- | -- | -- | -- | -- | -- | -- | -17.12 | 0.9581 | -- | -100.00 | -- | -58.00 | -- | -- | -- |
| Health Advance Inc | -100.00bn | -100.00bn | 204.37k | 3.00 | -- | 0.0473 | -- | -- | -- | -- | -- | 0.0212 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0356 | -- | 100.00 | -- | -21.75 | -- | -- | -- |
| CNBX Pharmaceuticals Inc | 230.08k | -1.21m | 220.89k | 2.00 | -- | -- | -- | 0.9601 | -0.0458 | -0.0458 | 0.0081 | -0.0789 | 0.6201 | -- | -- | 115,040.00 | -325.63 | -73.32 | -- | -99.80 | 14.96 | -- | -525.10 | -3,970.88 | -- | -1.34 | -- | -- | -- | 111.90 | 0.3497 | -- | -- | -- |
| Propanc Biopharma Inc | 0.00 | -2.46m | 223.10k | 1.00 | -- | -- | -- | -- | -0.3033 | -0.3033 | 0.00 | -0.0337 | 0.00 | -- | -- | -- | -2,440.90 | -4,945.87 | -- | -- | -- | -- | -- | -- | -- | -1.70 | -- | -- | -- | -- | -17.63 | -- | -- | -- |
